Union Savings Bank Takes Position in Bristol Myers Squibb Company $BMY

Union Savings Bank purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 9,722 shares of the biopharmaceutical company’s stock, valued at approximately $524,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Bristol Myers Squibb by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares in the last quarter. State Street Corp grew its position in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after buying an additional 1,385,206 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at $1,947,272,000. Finally, AQR Capital Management LLC increased its stake in shares of Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after buying an additional 16,332,924 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.2%

NYSE BMY opened at $54.10 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm has a market cap of $110.48 billion, a PE ratio of 15.20, a price-to-earnings-growth ratio of 0.15 and a beta of 0.24. The company has a 50 day moving average price of $57.34 and a 200 day moving average price of $57.09. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.7%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BMY. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Piper Sandler reissued an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target for the company. Guggenheim reaffirmed a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Finally, HSBC increased their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.